Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
复制标题
DOI：
10.1038/s41586-021-03471-w
复制
发表时间：
2021-05
期刊：
影响因子：
64.8
通讯作者：
中科院分区：
文献类型：
--
作者：
SARS-CoV-2关注变种(VOC)已经在多个地点独立出现，可能会降低目前针对SARS-CoV-2刺激性糖蛋白的疫苗的效力。在这里，我们使用活病毒中和试验，比较了非VOC变体和501Y.V2 VOC(也称为B.1.351)的中和效果，使用的血浆来自南非两波感染期间因新冠肺炎住院的成年人的血浆，第二波感染主要是501Y.V2变体的感染。测序表明，第一波献血员感染的病毒不包含与501Y.V2相关的突变，但有一例感染包含受体结合区的E484K替换。501Y.V2病毒变异株可有效地被第二波感染患者的血浆中和。第一波病毒变异株有效地被第一波感染的血浆中和。然而，来自第一波感染者的血浆对501Y.V2变异体的交叉中和作用很差；与第二波感染者的血浆对501Y.V2的中和作用相比，其效力降低了15.1倍。相比之下，使用第二波感染者的血浆交叉中和第一波病毒变体更有效，与第一波感染者的血浆中和第一波病毒变体相比，只减少了2.3倍。虽然我们只测试了一个感染SARS-CoV-2变种的人的一个血浆样本，只有E484K替换，但这个血浆样本有效地中和了两个变种。观察到来自501Y.V2感染者的血浆对第一波病毒的有效中和作用，为基于VOC序列的疫苗可以保持对其他循环SARS-CoV-2谱系的活性提供了初步证据。
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS-CoV-2. Here, using a live-virus neutralization assay, we compared the neutralization of a non-VOC variant with the 501Y.V2 VOC (also known as B.1.351) using plasma collected from adults who were hospitalized with COVID-19 during the two waves of infection in South Africa, the second wave of which was dominated by infections with the 501Y.V2 variant. Sequencing demonstrated that infections of plasma donors from the first wave were with viruses that did not contain the mutations associated with 501Y.V2, except for one infection that contained the E484K substitution in the receptor-binding domain. The 501Y.V2 virus variant was effectively neutralized by plasma from individuals who were infected during the second wave. The first-wave virus variant was effectively neutralized by plasma from first-wave infections. However, the 501Y.V2 variant was poorly cross-neutralized by plasma from individuals with first-wave infections; the efficacy was reduced by 15.1-fold relative to neutralization of 501Y.V2 by plasma from individuals infected in the second wave. By contrast, cross-neutralization of first-wave virus variants using plasma from individuals with second-wave infections was more effective, showing only a 2.3-fold decrease relative to neutralization of first-wave virus variants by plasma from individuals infected in the first wave. Although we tested only one plasma sample from an individual infected with a SARS-CoV-2 variant with only the E484K substitution, this plasma sample potently neutralized both variants. The observed effective neutralization of first-wave virus by plasma from individuals infected with 501Y.V2 provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
64.5
作者：
Garcia-Beltran, Wilfredo F.;Lam, Evan C.;Balazs, Alejandro B.
通讯作者：
Balazs, Alejandro B.
影响因子：
64.8
作者：
Sigal, Alex;Kim, Jocelyn T.;Baltimore, David
通讯作者：
Baltimore, David
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group
影响因子：
7.7
作者：
Weisblum, Yiska;Schmidt, Fabian;Bieniasz, Paul D
通讯作者：
Bieniasz, Paul D